https://www.selleckchem.com/pr....oducts/XL765(SAR2454
0025) were different from group E. Additional intertreatment group differences were found. Extracorporeal shock wave therapy caused a dose-dependent release of bupivacaine; however, there was no significant release of bupivacaine from liposomes when ESWT was applied at currently recommended therapeutic settings in this model. This in vitro study provides evidence that concurrent electrohydraulic ESWT and liposomal bupivacaine is likely safe at currently recommended settings, however, higher energy and pulse frequency settings s
Like
Comment
Share
